<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment and prognosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome in children
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment and prognosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome in children
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment and prognosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome in children
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Patrick Niaudet, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Olivia Gillion Boyer, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Tej K Mattoo, MD, DCH, FRCP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alison G Hoppin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 30, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The hemolytic uremic syndrome (HUS) is defined by the simultaneous occurrence of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury (AKI) [
         <a href="#rid1">
          1
         </a>
         ]. The most common cause of HUS is due to Shiga toxin-producing
         <em>
          Escherichia
         </em>
         <em>
          coli
         </em>
         (STEC), and it is one of the main causes of AKI in children under the age of three years.
        </p>
        <p>
         The treatment and prognosis of STEC-HUS is reviewed here. The clinical manifestations and diagnosis of STEC-HUS are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6081.html" rel="external">
          "Clinical manifestations and diagnosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome in children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1960222712">
         <span class="h1">
          DEFINITIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thrombotic microangiopathy (TMA)
         </strong>
         – TMA describes a specific pathologic lesion in which abnormalities in the vessel wall of arterioles and capillaries lead to microvascular thrombosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hemolytic uremic syndrome (HUS)
         </strong>
         – HUS is defined by the sudden onset of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury (AKI). It is a form of TMA most commonly caused by Shiga toxin-producing
         <em>
          Escherichia
         </em>
         <em>
          coli
         </em>
         (STEC). Other forms of TMA are complement-mediated HUS or TMA or thrombotic thrombocytopenic purpura. (See
         <a class="medical medical_review" href="/z/d/html/88648.html" rel="external">
          "Diagnostic approach to suspected TTP, HUS, or other thrombotic microangiopathy (TMA)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1072009412">
         <span class="h1">
          CLASSIFICATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the past, HUS had been divided into diarrhea-positive and diarrhea-negative HUS. The former, also referred to as typical HUS, primarily resulted from Shiga toxin-producing
         <em>
          E
         </em>
         .
         <em>
          coli
         </em>
         (STEC) infections, and less frequently from
         <em>
          Shigella
         </em>
         <em>
          dysenteriae
         </em>
         type 1 infection. All other causes of HUS were referred to as atypical HUS or assigned to the diarrhea-negative HUS, even though some patients with non-STEC-associated HUS also presented with diarrhea.
        </p>
        <p>
         However, ongoing research has provided a better understanding of the underlying causes of HUS, especially those due to genetic mutations in the alternative pathway of complement [
         <a href="#rid2">
          2,3
         </a>
         ]. As a result, the following classification has been developed based on pathophysiologic considerations and triggering factors [
         <a href="#rid4">
          4
         </a>
         ]. For this topic, patients identified as either having typical or diarrhea-positive HUS would be diagnosed with acquired HUS due to STEC. In addition, verotoxin, an alternate term for Shiga toxin, has been used extensively in the literature.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hereditary causes of TMA/HUS [
         <a href="#rid5">
          5
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Complement gene variants
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Inborn errors of cobalamin C metabolism
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Diacylglycerol kinase epsilon (
         <em>
          DGKE
         </em>
         ) gene mutations (see
         <a class="medical medical_review" href="/z/d/html/89549.html" rel="external">
          "Overview of hemolytic uremic syndrome in children", section on 'Coagulation pathway'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acquired causes of TMA/HUS:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Infection:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         STEC (see
         <a class="medical medical_review" href="/z/d/html/6081.html" rel="external">
          "Clinical manifestations and diagnosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome in children"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <em>
          Streptococcus
         </em>
         <em>
          pneumoniae
         </em>
         (see
         <a class="medical medical_review" href="/z/d/html/89549.html" rel="external">
          "Overview of hemolytic uremic syndrome in children", section on 'Streptococcus pneumoniae'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Human immunodeficiency virus (HIV) infection
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Autoantibodies to complement factors
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Drug toxicity, particularly in patients with cancer or solid organ transplant recipients
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Rare occurrences in pregnant patients or those with autoimmune disorders (eg, systemic lupus erythematous)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PREVENTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prevention of STEC-HUS rests, in part, on measures aimed at reducing the risk of STEC infection. These preventive measures, including public health measures, are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2711.html" rel="external">
          "Shiga toxin-producing Escherichia coli: Microbiology, pathogenesis, epidemiology, and prevention", section on 'Prevention'
         </a>
         .)
        </p>
        <p>
         Once a patient is infected with STEC, attempts to prevent progression from the bloody diarrheal phase (acute infectious phase) to the postdiarrheal phase of HUS have been largely unsuccessful (eg, antimotility drugs and antibiotics). However, it appears that maintaining adequate hydration may reduce the severity of STEC-HUS.
        </p>
        <p class="headingAnchor" id="H3942307033">
         <span class="h2">
          Hydration
         </span>
         <span class="headingEndMark">
          —
         </span>
         Maintaining adequate hydration during the diarrheal phase of STEC infection may reduce the severity of STEC-HUS [
         <a href="#rid6">
          6
         </a>
         ]. A systematic review of randomized trials and observational studies supported the benefit of vigorous fluid repletion during the diarrheal phase of STEC infection to reduce the severity of HUS [
         <a href="#rid7">
          7
         </a>
         ]. In this review, elevated hematocrit (measure of inadequate hydration) was associated with oligoanuria (odds ratio [OR] 2.38, 95% CI 1.30-4.35), kidney replacement therapy (OR 1.90, 95% CI 1.25-2.90), and death (OR 5.13, 95% CI, 1.50-17.57), whereas administration of intravenous (IV) fluids up to the day of HUS diagnosis was associated with a decreased risk of kidney replacement therapy (OR 0.26, 95% CI, 0.11-0.60). Mortality was increased for clinically dehydrated patients compared with hydrated patients (OR 3.71, 95% CI 1.25-11.03).
        </p>
        <p>
         In a subsequent large retrospective study of children with STEC, risk factors based on multivariate analysis for HUS included young age, elevation of hematocrit, platelet count and serum creatinine, low serum sodium, and administration of IV fluid ≥4 days following diarrhea onset [
         <a href="#rid8">
          8
         </a>
         ]. In addition, a small study reported that volume expansion with normal
         <a class="drug drug_pediatric" data-topicid="12796" href="/z/d/drug information/12796.html" rel="external">
          saline
         </a>
         given to 16 patients improved outcome compared with 19 historical controls [
         <a href="#rid9">
          9
         </a>
         ]. Indirect data suggest that increased hemoconcentration was associated with more severe HUS [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         Although these data suggest an association between volume depletion and adverse outcomes related to STEC-HUS, no studies directly evaluated the effect of hydration during STEC infections on the risk of developing HUS. Nevertheless, these limited data suggest that early parenteral volume expansion with isotonic IV solutions during STEC infections for patients who are volume depleted is associated with attenuated acute kidney injury (AKI). Further research is needed to unequivocally determine whether volume expansion can reduce the risk of HUS or its severity. In addition, there is evidence that suggests a need to maintain adequate hydration during the acute phase of HUS, which is discussed below. (See
         <a class="local">
          'Fluid management'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H114317253">
         <span class="h2">
          Potentially harmful interventions
         </span>
         <span class="headingEndMark">
          —
         </span>
         The challenge of identifying any preventative treatments for STEC-HUS was illustrated by a review of the literature that found four small trials that investigated four different interventions (antibiotics [
         <a class="drug drug_pediatric" data-topicid="12865" href="/z/d/drug information/12865.html" rel="external">
          trimethoprim
         </a>
         ‐sulfamethoxazole], anti-Shiga toxin antibody-containing bovine colostrum, Shiga toxin-binding agent, and a monoclonal antibody against Shiga toxin [urtoxazumab]) [
         <a href="#rid11">
          11
         </a>
         ]. However, there was no conclusion regarding effectiveness or risks, because of the small number of trials that included small sample sizes.
        </p>
        <p>
         The following interventions should be
         <strong>
          avoided
         </strong>
         in patients with suspected or confirmed STEC infections:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antibiotics
         </strong>
         – Antibiotic therapy is not recommended to treat suspected or confirmed STEC infections. This is based on limited evidence that antibiotic therapy is associated with a modest
         <strong>
          increase
         </strong>
         in risk of developing HUS [
         <a href="#rid12">
          12,13
         </a>
         ]. The evidence and rationale are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2714.html" rel="external">
          "Shiga toxin-producing Escherichia coli: Clinical manifestations, diagnosis, and treatment", section on 'Antibiotics'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Antimicrobial therapy does not appear to increase the risk of
         <em>
          S
         </em>
         .
         <em>
          dysenteriae
         </em>
         type 1-associated HUS [
         <a href="#rid14">
          14
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2718.html" rel="external">
          "Shigella infection: Epidemiology, clinical manifestations, and diagnosis", section on 'Hemolytic-uremic syndrome (HUS)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antimotility drugs
         </strong>
         – Antimotility drugs (such as anticholinergic agents and narcotics) are not recommended for patients with suspected or confirmed STEC infections. These drugs do not reduce the progression to HUS due to STEC infections and may
         <strong>
          increase
         </strong>
         the risk of subsequent development of STEC-HUS. In one retrospective review of 278 children with HUS, the use of antimotility drugs (anticholinergic agents and narcotics) was associated with an increased risk of subsequent development of HUS (OR 2.9, 95% CI 1.2-7.5) [
         <a href="#rid15">
          15
         </a>
         ]. In another retrospective study of 91 patients, antimotility drugs (anticholinergic agents and narcotics) increased the risk of central nervous system (CNS) dysfunction (OR 8.5, 95% CI 1.7-42.8) [
         <a href="#rid16">
          16
         </a>
         ]. There was no difference in the duration of diarrhea between patients who received antimotility drugs and those who did not.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nonsteroidal antiinflammatory drugs (NSAIDs)
         </strong>
         – NSAIDs should be avoided as they may cause acute kidney injury during the diarrheal phase of STEC infection [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H29385062">
         <span class="h1">
          MANAGEMENT OVERVIEW
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management of STEC-HUS is primarily based on supportive care because there is no proven safe and beneficial specific therapeutic intervention (see
         <a class="local">
          'Supportive therapy'
         </a>
         below). However,
         <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">
          eculizumab
         </a>
         and/or plasma therapy may be considered in patients with severe central nervous system (CNS) involvement (eg, seizures or coma) who have a poor prognosis. (See
         <a class="local">
          'Directed intervention for STEC-hemolytic uremic syndrome'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          SUPPORTIVE THERAPY
         </span>
        </p>
        <p class="headingAnchor" id="H29385056">
         <span class="h2">
          Overview
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prognosis of HUS has improved, in part because of the early institution of supportive therapy and improvements in intensive care and kidney replacement therapy. Appropriate care should be given for the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anemia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thrombocytopenia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fluid and electrolyte disturbances
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute kidney injury (AKI)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypertension
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neurologic dysfunction
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other organ involvement including colon, heart, pancreas, and lung
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Anemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with HUS can become profoundly and rapidly anemic. Based on clinical experience, packed red blood cells should be transfused when the hemoglobin (Hgb) level is &lt;6 g/dL or hematocrit &lt;18 percent to avoid cardiovascular and pulmonary compromise. Approximately 90 percent of children with STEC-HUS require red blood cell transfusions [
         <a href="#rid18">
          18
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5910.html" rel="external">
          "Red blood cell transfusion in infants and children: Indications"
         </a>
         .)
        </p>
        <p>
         A post-transfusion goal of an Hgb level between 8 and 9 g/dL is recommended to prevent cardiac and pulmonary complications resulting from high output cardiac failure. The goal is
         <strong>
          not
         </strong>
         to restore the Hgb level to normal, because the increased volume may cause heart failure, pulmonary edema, and hypertension [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
         Because of the concerns of hypervolemia, clinically indicated transfusions should be given slowly and cautiously with frequent monitoring of the patient's vital signs [
         <a href="#rid20">
          20
         </a>
         ]. In our practice, we typically administer packed red blood cells at a total volume of 10 mL/kg over three to four hours, which typically raises the Hgb level by 1 g/dL. Transfusions should be stopped if the vital signs suggest cardiopulmonary vascular overload (eg, hypertension, tachycardia, and/or tachypnea). In addition, serum or plasma potassium should be closely monitored due to the risk of hyperkalemia for patients with acute kidney injury. Blood products should be volume-reduced and preferably depleted of leukocytes and platelets to avoid alloimmunization (thus reducing the risk of graft rejection in patients who may subsequently require kidney transplantation). If the patient is undergoing hemodialysis, transfusions should be given during dialysis to minimize the risks of hypervolemia and hyperkalemia. (See
         <a class="medical medical_review" href="/z/d/html/5938.html" rel="external">
          "Red blood cell transfusion in infants and children: Administration and complications", section on 'Administration'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5935.html" rel="external">
          "Red blood cell transfusion in infants and children: Selection of blood products", section on 'Leukoreduced red blood cells'
         </a>
         .)
        </p>
        <p>
         Most patients do not require iron therapy, as iron from hemolyzed blood is available for erythropoiesis. In addition, there is
         <strong>
          no
         </strong>
         indication for the routine use of erythropoietin.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Thrombocytopenia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Platelet transfusion is reserved for patients with HUS who have significant clinical bleeding or if an invasive procedure is required [
         <a href="#rid20">
          20
         </a>
         ]. In our practice, we limit platelet transfusions to patients with active bleeding.
        </p>
        <p>
         Platelet transfusions are uncommon, as clinically significant bleeding is infrequent because the platelet count rarely falls below 10,000/mm
         <sup>
          3
         </sup>
         , and platelet production and function are normal. In one retrospective study, there were no bleeding complications in 73 patients who required an invasive procedure (ie, peritoneal dialysis catheter or central venous catheter placement) [
         <a href="#rid21">
          21
         </a>
         ]. In this cohort, the mean platelet counts were 37,600/mm
         <sup>
          3
         </sup>
         in patients who received platelet transfusions and 64,800/mm
         <sup>
          3
         </sup>
         in those not receiving transfusions.
        </p>
        <p>
         Although there has been a theoretical concern that platelet transfusion contributes to new or expanding thrombi due to consumption of infused platelets, as reported in adults with thrombotic thrombocytopenic purpura [
         <a href="#rid22">
          22,23
         </a>
         ], limited data in children suggest that platelet transfusion does not exacerbate the course of the disease [
         <a href="#rid24">
          24
         </a>
         ]. However, platelet transfusion may induce anti-human leukocyte antigen (HLA) antibodies, which may be deleterious later if the patient progresses to kidney failure and undergoes kidney transplantation.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Fluid and electrolyte management
         </span>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h3">
          Fluid management
         </span>
         <span class="headingEndMark">
          —
         </span>
         The standard fluid management of patients with HUS has been based on careful assessment since competing processes can lead to either decreased or increased intravascular volume [
         <a href="#rid20">
          20
         </a>
         ]. Decreased volume may result from vomiting, decreased oral intake, or diarrhea, while increased intravascular volume may arise from oliguria or anuria. As a result, fluid management is based on the intravascular fluid status of the patient and kidney function:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with decreased intravascular volume are repleted to a euvolemic state, whereas those with increased intravascular volume and diminished urine output are fluid restricted. Some may require kidney replacement therapy to remove fluid, especially if there is cardiac and pulmonary compromise. (See
         <a class="local">
          'Acute kidney injury'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Once the patient is in a euvolemic state, administration of fluids should be given as insensible losses plus urine output until kidney function returns to normal. Frequent monitoring of fluid balance, weight, and vital signs is imperative throughout the course of the acute process.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At the first sign of hypertension or cardiopulmonary overload, fluids should be restricted. Diuretics rarely avert anuria, but a trial of
         <a class="drug drug_pediatric" data-topicid="13329" href="/z/d/drug information/13329.html" rel="external">
          furosemide
         </a>
         (2 to 5 mg/kg per dose) may be attempted to induce a diuresis, particularly in patients with cardiopulmonary overload. Diuretics should not be continued in the patient who fails to respond. Dialysis therapy is required if fluid restriction and/or diuretic therapy fail to improve the compromised cardiorespiratory status of the patient in a timely manner. (See
         <a class="medical medical_review" href="/z/d/html/6090.html" rel="external">
          "Prevention and management of acute kidney injury (acute renal failure) in children"
         </a>
         and
         <a class="local">
          'Acute kidney injury'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         Limited data from small observational studies suggest that judicious volume expansion early in the course of HUS may reduce the risk of kidney replacement therapy (KRT). An Italian study from 2012 and 2014 reported that early volume expansion targeted to increase body weight by 10 percent improved outcome for 38 children with STEC-HUS compared to historical controls from 2006 to 2009 [
         <a href="#rid25">
          25
         </a>
         ]. In this study, patients with intravenous (IV) fluid infusion resulting in a mean increase in body weight of 12.5 percent after 48 hours of hospitalization had a lower rate of KRT (26 versus 58 percent), shorter hospital course (9 versus 12 days), and shorter duration of intensive care (2 versus 9 days) compared with the historical control group. There was a trend for a lower risk of central nervous system (CNS) involvement with early volume expansion (8 versus 24 percent), although this was not statistically significant. In the volume expansion group, there were no serious adverse effects. One patient had evidence of fluid overload (eg, hypertension) that responded to diuretic (eg,
         <a class="drug drug_pediatric" data-topicid="13329" href="/z/d/drug information/13329.html" rel="external">
          furosemide
         </a>
         ) therapy. A second Italian study reported that 16 children with STEC-HUS treated with volume expansion had a lower risk of KRT compared with historical controls who did not receive volume expansion [
         <a href="#rid9">
          9
         </a>
         ]. Although these results are encouraging, it should be noted that there is a concern for potential bias with the use of historical controls with potential difference in severity of disease and treatment, and the relatively small number of patients. Nevertheless, these findings should prompt further investigations to confirm the potential benefit of early volume expansion in all children with STEC-HUS.
        </p>
        <p>
         Based on these results, we agree that fluid management should be directed to rapidly correct any volume depletion, which is a common fluid state of patients with STEC-HUS. However, until further evidence is provided, we do not recommend routine volume expansion without proper assessment of intravascular volume status and kidney function, especially if there is evidence of increased intravascular volume.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h3">
          Electrolyte management
         </span>
         <span class="headingEndMark">
          —
         </span>
         Electrolyte disturbances are common, usually due to acute kidney function impairment or kidney failure. They include hyperkalemia, hyperphosphatemia, and metabolic acidosis. Management of these disorders is the same as in patients with other causes of AKI and is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/6090.html" rel="external">
          "Prevention and management of acute kidney injury (acute renal failure) in children", section on 'Electrolyte management'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Acute kidney injury
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Drug management
         </strong>
         – In patients with HUS who develop kidney function impairment or kidney failure, nephrotoxic medications should be stopped and nonsteroidal antiinflammatory drugs (NSAIDS) should not be used. The dosing of drugs that are excreted by the kidney also must be readjusted for kidney dysfunction. (See
         <a class="medical medical_review" href="/z/d/html/6090.html" rel="external">
          "Prevention and management of acute kidney injury (acute renal failure) in children", section on 'Drug management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Kidney replacement therapy
         </strong>
         – There is no evidence that early dialysis affects clinical outcome. As a result, the indications for dialysis in children with HUS are similar to those in children with other forms of AKI. These include the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Signs and symptoms of uremia
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Azotemia defined as blood urea nitrogen ≥80 to 100 mg/dL (29 to 36 mmol/L)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Severe fluid overload (eg, cardiopulmonary compromise and/or hypertension) that is refractory to medical therapy
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Severe electrolyte abnormalities (eg, hyperkalemia and acidosis) that are refractory to medical therapy
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Need for nutritional support in a child with oliguria or anuria
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         (See
         <a class="medical medical_review" href="/z/d/html/15895.html" rel="external">
          "Pediatric acute kidney injury: Indications, timing, and choice of modality for kidney replacement therapy", section on 'Indication and timing for kidney replacement therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The choice of kidney replacement modalities varies among pediatric nephrologists and medical centers. In most young children, peritoneal dialysis is selected [
         <a href="#rid26">
          26
         </a>
         ]. However, there is no evidence of increased benefit of peritoneal dialysis compared with hemodialysis. If there is a severe abdominal complication requiring surgical intervention, peritoneal dialysis is contraindicated. In our center, IV antibiotic prophylaxis is administered prior to PD catheter placement to reduce the risk of peritonitis [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Hypertension
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with HUS, hypertension is caused by ischemia-induced activation of the renin-angiotensin system and/or overexpansion of intravascular volume [
         <a href="#rid27">
          27
         </a>
         ]. Management is directed toward correcting the fluid status and the use of antihypertensive agents. (See
         <a class="local">
          'Fluid management'
         </a>
         above.)
        </p>
        <p>
         During the acute phase of HUS, we suggest treating hypertension with calcium channel blockers (such as
         <a class="drug drug_pediatric" data-topicid="12643" href="/z/d/drug information/12643.html" rel="external">
          nifedipine
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12925" href="/z/d/drug information/12925.html" rel="external">
          nicardipine
         </a>
         ) because of the concern of reduced kidney perfusion with angiotensin-converting enzyme (ACE) inhibitors  (
         <a class="graphic graphic_table graphicRef71466" href="/z/d/graphic/71466.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid20">
          20
         </a>
         ]. In contrast, some other experts may use an ACE inhibitor because of patient response and the potential renoprotective effect in children with long-term sequelae of HUS (eg, proteinuria, kidney function impairment, and hypertension) [
         <a href="#rid28">
          28,29
         </a>
         ].
        </p>
        <p>
         After the acute phase of HUS, we suggest that antihypertensive therapy be changed to ACE inhibitors in patients who appear to have long-term kidney sequelae. Long-term ACE inhibitor therapy may be beneficial as it reduces protein excretion, which may retard chronic kidney disease (CKD) progression as well as lower blood pressure in hypertensive patients. (See
         <a class="medical medical_review" href="/z/d/html/7169.html" rel="external">
          "Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults", section on 'Effect of antihypertensive drugs on proteinuria'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/128353.html" rel="external">
          "Chronic kidney disease in children: Complications", section on 'Hypertension'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Neurologic dysfunction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Serious complications of the CNS, such as seizures, strokes, and decreased level of consciousness occurring in 10 percent of cases are predictors of poor outcome [
         <a href="#rid30">
          30
         </a>
         ]. In any patient with HUS who presents with serious neurologic dysfunction (eg, seizure and coma), radiologic imaging should be performed to assess and confirm CNS involvement. (See
         <a class="medical medical_review" href="/z/d/html/6081.html" rel="external">
          "Clinical manifestations and diagnosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome in children", section on 'Other organ involvement'
         </a>
         .)
        </p>
        <p>
         Management issues regarding children with CNS involvement include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">
          Eculizumab
         </a>
         therapy appears to improve neurologic outcome and is our preferred therapy in patients with severe CNS involvement. (See
         <a class="local">
          'Eculizumab'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Plasma therapy
         </strong>
         has an uncertain role in patients with STEC-HUS. Although it is often used in patients with severe CNS involvement (eg, seizure or stroke), we do not routinely provide plasma therapy in this clinical setting. Plasma therapy is often beneficial in patients with complement-mediated HUS. (See
         <a class="local">
          'Plasma infusion and plasma exchange'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/6084.html" rel="external">
          "Complement-mediated hemolytic uremic syndrome in children", section on 'Plasma therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Severe hypertension
         </strong>
         may be a contributing factor for CNS involvement. In these patients, control of significantly elevated blood pressure will result in resolution of some of the CNS manifestations.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Seizures
         </strong>
         are treated with parenteral antiepileptic agents. These include
         <a class="drug drug_pediatric" data-topicid="13223" href="/z/d/drug information/13223.html" rel="external">
          diazepam
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12702" href="/z/d/drug information/12702.html" rel="external">
          phenytoin
         </a>
         , and fos-phenytoin. Seizures also may be secondary to severe hypertension, which become refractory without appropriate blood pressure control. (See
         <a class="medical medical_review" href="/z/d/html/6192.html" rel="external">
          "Management of convulsive status epilepticus in children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Other organ involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although not as common as kidney and neurologic complications, patients may develop severe gastrointestinal complications, cardiac dysfunction, and pancreatitis [
         <a href="#rid31">
          31-33
         </a>
         ]. In addition, respiratory complications secondary to increased intravascular volume may occur. Management for these potential complications includes the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gastrointestinal complications – Severe colitis may progress to necrosis and in some cases intestinal perforation. Management includes serial abdominal examinations, guaiac testing of the stool, and the use of parenteral nutrition. Surgical intervention may be required.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cardiac dysfunction – Cardiac dysfunction can be a result of cardiac ischemia and fluid overload. Pericarditis may be associated with uremia. Appropriate therapy should be directed to the underlying pathology and may include inotropic agents, fluid restriction, and/or dialysis. Measurement of troponin levels may be useful to detect myocardial ischemia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pancreatitis – Clinically significant pancreatitis can occur resulting in insulin deficiency. Insulin therapy may be required for hyperglycemia. (See
         <a class="medical medical_review" href="/z/d/html/5633.html" rel="external">
          "Management of acute pancreatitis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pulmonary complications – Pulmonary edema and effusions may result from intravascular fluid overload. Management may include fluid restriction, diuretics, dialysis, and/or ventilatory support.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h1">
          DIRECTED INTERVENTION FOR STEC-HEMOLYTIC UREMIC SYNDROME
         </span>
        </p>
        <p class="headingAnchor" id="H29385050">
         <span class="h2">
          Overview
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple modalities and/or agents have been utilized that are directed against the underlying or presumed pathogenic mechanisms of STEC-HUS. These include antithrombotic agents, plasma exchange and/or plasma infusion, tissue-type plasminogen activator, and oral Shiga toxin-binding agent.
        </p>
        <p>
         Although none of these agents have been shown to be efficacious, there may be a role for
         <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">
          eculizumab
         </a>
         (a monoclonal antibody that blocks complement activity by cleavage of C5) and plasma infusion/exchange in patients with serious central nervous system (CNS; seizures, strokes, and decreased level of consciousness) involvement. In our center, we prefer the use of eculizumab, however, this medication is expensive and may not be universally available. The remaining agents are
         <strong>
          not
         </strong>
         recommended.
        </p>
        <p class="headingAnchor" id="H4043038">
         <span class="h2">
          Eculizumab
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">
          Eculizumab
         </a>
         , a monoclonal antibody to complement factor C5 that blocks complement activation, has been used in the treatment of patients with complement-mediated HUS, but data are inconclusive regarding effectiveness in STEC-HUS [
         <a href="#rid34">
          34-39
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications and efficacy
         </strong>
         – We administer
         <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">
          eculizumab
         </a>
         to patients with STEC-HUS and severe CNS involvement (eg, seizures, coma, neurologic defect) because these patients are at significant risk for death and long-term morbidity. A "neurologic score" has been proposed to guide when eculizumab should be used to treat CNS complications [
         <a href="#rid36">
          36
         </a>
         ]. However, further study is needed to validate its clinical use. We also consider eculizumab in cases of other severe organ involvement, such as cardiac dysfunction. However, this medication is costly and so may not be available because of the prohibitive cost. (See
         <a class="local">
          'Prognosis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">
          Eculizumab
         </a>
         is beneficial in treating patients with complement-mediated HUS (see
         <a class="medical medical_review" href="/z/d/html/6084.html" rel="external">
          "Complement-mediated hemolytic uremic syndrome in children", section on 'Complement blockade (eculizumab)'
         </a>
         ). Several small case series have also shown that eculizumab may be beneficial in patients with STEC-HUS and CNS involvement [
         <a href="#rid36">
          36,40-44
         </a>
         ]. In contrast, no benefit was seen with the administration of eculizumab over standard care for patients treated in the 2011 outbreak of
         <em>
          E
         </em>
         .
         <em>
          coli
         </em>
         O104:H4 [
         <a href="#rid45">
          45-47
         </a>
         ]. However, the administration of eculizumab was often delayed after plasma exchange.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a randomized trial involving 100 children with STEC-HUS,
         <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">
          eculizumab
         </a>
         did not appear to be associated with improved kidney outcome during the acute phase, but the proportion of patients experiencing kidney sequelae at one year was lower in the eculizumab group than in the placebo group (43.48 and 64.44 percent, respectively) [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Additional support for the use of
         <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">
          eculizumab
         </a>
         is provided by the in-vitro demonstration that complement activation occurs in STEC-HUS [
         <a href="#rid49">
          49-53
         </a>
         ]. It has also been shown that Shiga toxin directly activates complement via the alternative pathway through its binding to complement factor H and complement factor H-related protein [
         <a href="#rid54">
          54,55
         </a>
         ]. These findings provide a rationale for the use of eculizumab with evidence that complement activation contributes to the inflammatory and prothrombotic mechanisms that are involved in the pathogenesis of STEC-HUS.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing
         </strong>
         – The dosing of
         <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">
          eculizumab
         </a>
         is based on a regimen used in a clinical trial for eculizumab treatment in patients with complement-mediated HUS. (See
         <a class="medical medical_review" href="/z/d/html/6084.html" rel="external">
          "Complement-mediated hemolytic uremic syndrome in children", section on 'Complement blockade (eculizumab)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The following is the initial dosing of
         <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">
          eculizumab
         </a>
         to treat STEC-HUS, which is dependent on patient's body weight:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         5 to &lt;10 kg – 300 mg
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         10 to &lt;40 kg – 600 mg
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         ≥40 kg – 900 mg
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We usually administer a second dose at day 7 after the first dose. The decision for additional doses of
         <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">
          eculizumab
         </a>
         is dependent on the clinical status of the patient. We consider additional doses if the neurologic status has not normalized and/or if kidney function has not improved. If plasmapheresis therapy is also being performed, a repeat dose is given after each plasmapheresis session.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – Treatment with
         <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">
          eculizumab
         </a>
         is associated with potentially life-threatening risk of encapsulated bacterial infection (
         <em>
          Neisseria
         </em>
         <em>
          meningitidis
         </em>
         ,
         <em>
          S
         </em>
         .
         <em>
          pneumoniae
         </em>
         ,
         <em>
          Haemophilus
         </em>
         <em>
          influenzae)
         </em>
         as a result of terminal complement blockade. Therefore, children must receive meningococcal vaccination (both ACYW and serogroup B) before being treated with eculizumab as well as vaccination against
         <em>
          H
         </em>
         .
         <em>
          influenzae
         </em>
         and S.
         <em>
          pneumoniae
         </em>
         . Antibiotic prophylaxis is also recommended during eculizumab therapy. Antimicrobial prophylaxis for prevention of meningococcal infection consists of penicillin, dosage for patients ≥3 years of age of 250 mg orally twice a day and for children &lt;3 years of age 125 mg orally twice daily. In the presence of penicillin allergy, a macrolide can be substituted. (See
         <a class="medical medical_review" href="/z/d/html/1274.html" rel="external">
          "Treatment and prevention of meningococcal infection", section on 'Patients receiving C5 inhibitors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2896992322">
         <span class="h2">
          Plasma infusion and plasma exchange
         </span>
         <span class="headingEndMark">
          —
         </span>
         Plasma exchange has often been used in children with STEC-HUS and severe CNS involvement (eg, stroke) based on reported benefits of plasma exchange in adults with TTP and severe neurologic dysfunction. However, there is
         <strong>
          no
         </strong>
         evidence that it is beneficial in the treatment of STEC-HUS. As a result, we do not routinely administer plasma therapy as the initial treatment for patients with severe CNS involvement. In our center,
         <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">
          eculizumab
         </a>
         is the preferred initial intervention. If plasma exchange is performed, the volume of exchange is 40 to 60 mL/kg and fresh frozen plasma is generally used as the replacement fluid. (See
         <a class="medical medical_review" href="/z/d/html/1344.html" rel="external">
          "Immune TTP: Initial treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7941.html" rel="external">
          "Therapeutic apheresis (plasma exchange or cytapheresis): Indications and technology"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6084.html" rel="external">
          "Complement-mediated hemolytic uremic syndrome in children", section on 'Plasma therapy'
         </a>
         .)
        </p>
        <p>
         There are no randomized controlled studies that evaluate the efficacy of plasma exchange in children with STEC-HUS. Information is based on observational data:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         During the 2011
         <em>
          E
         </em>
         .
         <em>
          coli
         </em>
         O104:H4 outbreak in Germany, a benefit from plasma exchanges used alone or with steroids could not be demonstrated [
         <a href="#rid45">
          45
         </a>
         ]. During the same outbreak, five adult patients in southern Denmark were treated with daily plasma exchange early after onset and all had favorable outcome with normal neurologic status [
         <a href="#rid56">
          56
         </a>
         ]. Although a long-term follow-up study found an association between the use of plasma therapy during the acute phase and poor long-term outcome, it should be noted that plasma therapy was used more frequently in severe cases [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In an earlier meta-analysis that evaluated plasma exchange from four observational studies, there was
         <strong>
          no
         </strong>
         clinical benefit seen with plasma exchange in patients with STEC-HUS [
         <a href="#rid58">
          58
         </a>
         ]. However, the small number of studies that are observational in their design and the variability of the clinical spectrum of disease hamper the analysis.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1950583141">
         <span class="h2">
          Not recommended therapies
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antithrombotic therapy
         </strong>
         – We do not recommend antithrombotic agents in patients with STEC-HUS, because there is no evidence of clinical benefit and these agents are associated with increased risk of hemorrhagic complications.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The rationale for the use of antithrombotic agents in HUS was based on the histologic evidence of thrombus formation. However, this does not mean that antithrombotic agents are relevant, because HUS is primarily characterized by platelet rather than fibrin consumption. (See
         <a class="medical medical_review" href="/z/d/html/6081.html" rel="external">
          "Clinical manifestations and diagnosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome in children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Two prospective controlled trials have compared combinations of antithrombotic agents (eg, either urokinase and heparin or
         <a class="drug drug_pediatric" data-topicid="13241" href="/z/d/drug information/13241.html" rel="external">
          dipyridamole
         </a>
         and heparin) with supportive care or supportive care alone [
         <a href="#rid59">
          59,60
         </a>
         ]. The duration of kidney failure, hemolysis, and thrombocytopenia, and the long-term outcome were all similar in both control and treated groups. Furthermore, hemorrhagic complications were more common in the treated patients [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Oral Shiga toxin-binding agent
         </strong>
         – We do not recommend the use of oral Shiga toxin-binding agents. In a placebo-controlled randomized study of 145 children diagnosed with HUS, Synsorb-Pk, an oral agent that binds Shiga toxin, did not improve clinical outcome [
         <a href="#rid61">
          61
         </a>
         ]. The incidence of death or serious extrarenal events was the same in the treated and placebo control groups (18 and 20 percent, respectively).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Therapies targeting tissue-type plasminogen activators
         </strong>
         – We do not recommend therapies directed against tissue-type plasminogen activators. It has been suggested that plasminogen-activator inhibitor type 1 (PAI-1) may be a circulating inhibitor of fibrinolysis in HUS. In one report, administration of a monoclonal antibody to normalize plasma PAI-1 levels correlated with improvement in kidney function [
         <a href="#rid62">
          62
         </a>
         ]. Another case report described a successful response to
         <a class="drug drug_pediatric" data-topicid="13363" href="/z/d/drug information/13363.html" rel="external">
          alteplase
         </a>
         (recombinant tissue-type plasminogen activator) [
         <a href="#rid63">
          63
         </a>
         ]. However, these single case reports are insufficient evidence to support these agents except in a research setting.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The hematologic manifestations of STEC-HUS completely resolve usually within one to two weeks. The prognosis for recovery of kidney function is generally favorable, with resolution beginning after hematologic improvement, but up to one-third of patients develop mild kidney dysfunction in long-term follow-up (see
         <a class="local">
          'Long-term outcome'
         </a>
         below). The mortality rate is less than 5 percent [
         <a href="#rid18">
          18,64-66
         </a>
         ], but another 5 percent of patients have significant sequelae (eg, stroke or kidney failure) [
         <a href="#rid64">
          64
         </a>
         ]. Long-term outcome results generally are from data of patients with
         <em>
          E
         </em>
         .
         <em>
          coli
         </em>
         0157:H7-associated HUS, although a similar favorable outcome has been observed in children who were affected during the large German HUS outbreak in 2011 due to
         <em>
          E
         </em>
         .
         <em>
          coli
         </em>
         O104:H4 [
         <a href="#rid67">
          67
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6081.html" rel="external">
          "Clinical manifestations and diagnosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome in children", section on 'Escherichia coli strains'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H182809768">
         <span class="h2">
          Acute mortality
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mortality typically occurs acutely during the initial hospitalization with reported rates of approximately 3 to 4 percent [
         <a href="#rid18">
          18,68
         </a>
         ]. Causes of death during the acute phase of HUS include central nervous system (CNS) injury (eg, cerebral edema, cerebral infarction, or brain death), hyperkalemia, coagulopathy, sepsis, heart failure, pulmonary hemorrhage, and injury to the gastrointestinal tract [
         <a href="#rid18">
          18,69
         </a>
         ].
        </p>
        <p>
         Reported factors associated with mortality include elevated white blood count, hematocrit greater than 20 percent, an episode of respiratory tract infection, particularly pneumonia due to
         <em>
          S
         </em>
         .
         <em>
          pneumoniae
         </em>
         , and hyponatremia [
         <a href="#rid18">
          18,68
         </a>
         ]. In a large retrospective study, all patients without bloody stools survived [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h2">
          Long-term outcome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approximately 60 to 70 percent of patients recover completely from the acute phase of STEC-HUS [
         <a href="#rid67">
          67,70
         </a>
         ]. In the remaining patients, there is a varying degree of the severity of sequelae, which are primarily due to initial kidney injury.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk factors
         </strong>
         – Children who have long-term complications from HUS often have one or more of the following risk factors during the acute phase of the disease [
         <a href="#rid64">
          64-66,70,71
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A WBC &gt;20,000 per mm
         <sup>
          3
         </sup>
         at presentation. The leukocytosis in part reflects neutrophil activation resulting from monocyte release of the neutrophil chemoattractant interleukin-8; these neutrophils may then contribute to tissue damage [
         <a href="#rid72">
          72
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Initial oliguria/anuria that is persistent (&gt;5 days of anuria and &gt;10 days of oliguria) and prolonged dialysis [
         <a href="#rid70">
          70,73
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Kidney histology showing a glomerular microangiopathy affecting &gt;50 percent of glomeruli, arterial microangiopathy, and/or cortical necrosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Shorter prodromal phase [
         <a href="#rid74">
          74
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Kidney outcomes
         </strong>
         – Although the glomerular filtration rate (GFR) returns to normal in most children with STEC-HUS, follow-up after the acute phase reveals evidence of irreversible kidney injury in 30 to 50 percent of children, including the following findings [
         <a href="#rid65">
          65-67,70,71,75,76
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hypertension
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Mild proteinuria (usually less than 1000 mg per day)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Subclinical decline in GFR with plasma creatinine concentration remaining in the normal range
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Chronic kidney disease (CKD) and kidney failure
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Long-term outcomes were illustrated in a report of 122 children with STEC-HUS who did not require dialysis, with median follow-up of 11.3 years [
         <a href="#rid76">
          76
         </a>
         ]. At last follow-up (median duration of 11.3 years), 67 percent had complete recovery of kidney function, 30 percent had stage 1 CKD, 3 percent had stage 2 CKD, and none had more advanced stages or kidney failure. One-half of the CKD developed within five years of STEC-HUS. A separate report that included children who required dialysis in the acute phase of STEC-HUS found that 28 percent (19/69) had proteinuria and 19 percent (14/72) were hypertensive after a median follow-up of three years [
         <a href="#rid67">
          67
         </a>
         ]. However, only two patients had ESRD: one who never recovered kidney function, and the other who was initially dialyzed and recovered during the acute phase but had deterioration of kidney function after 19 months resulting in reinitiation of dialysis after 44 weeks. One other patient had impaired kidney function with an estimated GFR of 53 mL/min per 1.73 m
         <sup>
          2
         </sup>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Thus, a normal GFR at late follow-up does not necessarily imply complete recovery of kidney function [
         <a href="#rid77">
          77
         </a>
         ]. Some patients with a normal serum creatinine have a persistent reduction in kidney blood flow and a lower-than-normal maximum GFR after a protein load [
         <a href="#rid78">
          78,79
         </a>
         ]. These findings suggest permanent nephron loss, with compensatory hyperfiltration in the surviving nephrons, which maintains the total filtration rate. Sequential kidney biopsies may show glomerular scarring, which could reflect secondary hemodynamically-mediated glomerular injury resulting from the initial nephron loss [
         <a href="#rid78">
          78
         </a>
         ] In addition, endothelial dysfunction may be observed during long-term follow-up in some children with STEC-HUS despite normal kidney function and blood pressure [
         <a href="#rid80">
          80
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7181.html" rel="external">
          "Secondary factors and progression of chronic kidney disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Recurrence after kidney transplantation
         </strong>
         – In patients with STEC-HUS who progress to kidney failure and undergo kidney transplantation, recurrence of HUS in the transplanted kidney is rare [
         <a href="#rid78">
          78,81-86
         </a>
         ]. In one review of 118 children, there was only one case of recurrence with allograft loss (0.8 percent) [
         <a href="#rid86">
          86
         </a>
         ]. Because it is rare that HUS recurs in normal patients, if there is a recurrence after kidney transplantation, an evaluation for an underlying mutation resulting in complement-mediated HUS should be performed [
         <a href="#rid5">
          5
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6084.html" rel="external">
          "Complement-mediated hemolytic uremic syndrome in children", section on 'Genetic variants'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In general, allograft survival in patients with STEC-HUS is similar to survival in those with other causes of CKD [
         <a href="#rid82">
          82
         </a>
         ]. However, the diagnosis of recurrence of HUS after kidney transplantation may be difficult. Although
         <a class="drug drug_pediatric" data-topicid="13193" href="/z/d/drug information/13193.html" rel="external">
          cyclosporine
         </a>
         and other calcineurin inhibitors have no detrimental effect on recurrence, these immunosuppressive agents may cause a nephropathy that has many features in common with HUS. In addition, it may be difficult to distinguish recurrence of HUS from severe acute vascular or chronic rejection on a kidney biopsy. (See
         <a class="medical medical_review" href="/z/d/html/89549.html" rel="external">
          "Overview of hemolytic uremic syndrome in children", section on 'Acquired non-infectious causes'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7357.html" rel="external">
          "Cyclosporine and tacrolimus nephrotoxicity"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h1">
          FOLLOW-UP
         </span>
         <span class="headingEndMark">
          —
         </span>
         Based on risks for progressive CKD described above [
         <a href="#rid70">
          70,76,87
         </a>
         ], patients with STEC-HUS should have yearly follow-up to monitor for signs of hypertension, proteinuria, and kidney function impairment, with ongoing monitoring during adulthood. Each visit should include blood pressure measurement and laboratory evaluation of kidney function including urinalysis and serum creatinine concentration. For patients who become pregnant, it is also recommended that follow-up care includes assessment for elevated blood pressure and proteinuria.
        </p>
        <p class="headingAnchor" id="H3328315086">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/117977.html" rel="external">
          "Society guideline links: Hemolytic uremic syndrome in children"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/117846.html" rel="external">
          "Society guideline links: Thrombotic microangiopathies (TTP, HUS, and related disorders)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition
         </strong>
         – Hemolytic uremic syndrome (HUS) is defined by the simultaneous occurrence of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury (AKI). The most common cause of HUS is due to Shiga toxin-producing
         <em>
          Escherichia
         </em>
         <em>
          coli
         </em>
         (STEC). (See
         <a class="local">
          'Definitions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         There is no known effective therapy to prevent progression from the bloody diarrheal phase (acute infectious phase) to the postdiarrheal phase of HUS.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In patients with confirmed or suspected infections due to enterohemorrhagic
         <em>
          E
         </em>
         .
         <em>
          coli
         </em>
         , we suggest that adequate hydration be maintained, including the use of early parenteral fluid for children during the diarrheal phase of STEC infection to avoid kidney hypoperfusion (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). We recommend
         <strong>
          against
         </strong>
         antimotility agents (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). (See
         <a class="local">
          'Prevention'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Antibiotic therapy is
         <strong>
          not
         </strong>
         recommended for individuals with confirmed or suspected STEC infections. (See
         <a class="medical medical_review" href="/z/d/html/2714.html" rel="external">
          "Shiga toxin-producing Escherichia coli: Clinical manifestations, diagnosis, and treatment", section on 'Avoid potentially harmful interventions'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management of acute phase
         </strong>
         – Therapy for STEC-HUS is supportive and includes (see
         <a class="local">
          'Supportive therapy'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Anemia
         </strong>
         – Patients with HUS can become profoundly and rapidly anemic and require red blood cell transfusions. In our clinical experience, we transfuse when the hemoglobin level falls below 6 g/dL. (See
         <a class="local">
          'Anemia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Thrombocytopenia
         </strong>
         – We suggest platelet transfusion only if there is active bleeding (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Thrombocytopenia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Fluids and electrolytes
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For each patient, the fluid status is assessed and management is directed toward returning the patient to a euvolemic state. This includes avoiding and correcting any volume depletion. Conversely, frequent monitoring of fluid balance, weight, and vital signs is required to detect early signs of fluid overload. If this occurs, prompt fluid restriction is begun. (See
         <a class="local">
          'Fluid management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Electrolytes should be monitored to detect hyperkalemia, hyperphosphatemia, and metabolic acidosis. Management of these disorders is the same as in patients with other causes of AKI. (See
         <a class="medical medical_review" href="/z/d/html/6090.html" rel="external">
          "Prevention and management of acute kidney injury (acute renal failure) in children", section on 'Electrolyte management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Dialysis therapy is initiated as indicated for AKI. (See
         <a class="medical medical_review" href="/z/d/html/6090.html" rel="external">
          "Prevention and management of acute kidney injury (acute renal failure) in children", section on 'Kidney replacement therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15895.html" rel="external">
          "Pediatric acute kidney injury: Indications, timing, and choice of modality for kidney replacement therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Hypertension
         </strong>
         – Hypertension is managed by fluid restriction, antihypertensive agents, and dialysis if needed. During the acute phase of the illness, we suggest the use of calcium channel blockers (such as
         <a class="drug drug_pediatric" data-topicid="12643" href="/z/d/drug information/12643.html" rel="external">
          nifedipine
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12925" href="/z/d/drug information/12925.html" rel="external">
          nicardipine
         </a>
         ) as the initial choice of antihypertensive agent (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Hypertension'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Neurologic dysfunction
         </strong>
         – In patients with severe neurologic involvement, we suggest administering
         <a class="drug drug_pediatric" data-topicid="109480" href="/z/d/drug information/109480.html" rel="external">
          eculizumab
         </a>
         , a monoclonal antibody to complement factor C5 that blocks complement activation (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Eculizumab'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Parenteral antiepileptic agents (eg,
         <a class="drug drug_pediatric" data-topicid="13223" href="/z/d/drug information/13223.html" rel="external">
          diazepam
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12702" href="/z/d/drug information/12702.html" rel="external">
          phenytoin
         </a>
         , and fos-phenytoin) are used in the management of seizures in patients with HUS. (See
         <a class="medical medical_review" href="/z/d/html/6192.html" rel="external">
          "Management of convulsive status epilepticus in children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         We do
         <strong>
          not
         </strong>
         recommend the use of antithrombotic agents or oral Shiga toxin-binding agent (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). (See
         <a class="local">
          'Not recommended therapies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         <strong>
          and follow up
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The short-term prognosis of STEC-HUS is favorable, with mortality rates below 5 percent. However, up to one-third of patients eventually develop chronic kidney disease (CKD) over the subsequent two decades and the risk of developing kidney failure is not negligible. In patients who require kidney transplantation, recurrence of HUS is rare. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Annual follow-up of patients with HUS should include blood pressure measurement, urinalysis, and serum creatinine. (See
         <a class="local">
          'Follow-up'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients who have recovered from the acute phase of HUS but develop chronic hypertension or other kidney sequelae, we suggest treatment with angiotensin-converting enzyme (ACE) inhibitors (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Hypertension'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Noris M, Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol 2005; 16:1035.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goodship TH, Cook HT, Fakhouri F, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int 2017; 91:539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fakhouri F, Zuber J, Frémeaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet 2017; 390:681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aigner C, Schmidt A, Gaggl M, Sunder-Plassmann G. An updated classification of thrombotic microangiopathies and treatment of complement gene variant-mediated thrombotic microangiopathy. Clin Kidney J 2019; 12:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loirat C, Fakhouri F, Ariceta G, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2016; 31:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freedman SB, van de Kar NCAJ, Tarr PI. Shiga Toxin-Producing Escherichia coli and the Hemolytic-Uremic Syndrome. N Engl J Med 2023; 389:1402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grisaru S, Xie J, Samuel S, et al. Associations Between Hydration Status, Intravenous Fluid Administration, and Outcomes of Patients Infected With Shiga Toxin-Producing Escherichia coli: A Systematic Review and Meta-analysis. JAMA Pediatr 2017; 171:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McKee RS, Schnadower D, Tarr PI, et al. Predicting Hemolytic Uremic Syndrome and Renal Replacement Therapy in Shiga Toxin-producing Escherichia coli-infected Children. Clin Infect Dis 2020; 70:1643.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonany P, Bilkis MD, Iglesias G, et al. Fluid restriction versus volume expansion in children with diarrhea-associated HUS: a retrospective observational study. Pediatr Nephrol 2021; 36:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loos S, Oh J, van de Loo L, et al. Hemoconcentration and predictors in Shiga toxin-producing E. coli-hemolytic uremic syndrome (STEC-HUS). Pediatr Nephrol 2021; 36:3777.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Imdad A, Mackoff SP, Urciuoli DM, et al. Interventions for preventing diarrhoea-associated haemolytic uraemic syndrome. Cochrane Database Syst Rev 2021; 7:CD012997.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tarr PI, Freedman SB. Why antibiotics should not be used to treat Shiga toxin-producing Escherichia coli infections. Curr Opin Gastroenterol 2022; 38:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freedman SB, Xie J, Neufeld MS, et al. Shiga Toxin-Producing Escherichia coli Infection, Antibiotics, and Risk of Developing Hemolytic Uremic Syndrome: A Meta-analysis. Clin Infect Dis 2016; 62:1251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bennish ML, Khan WA, Begum M, et al. Low risk of hemolytic uremic syndrome after early effective antimicrobial therapy for Shigella dysenteriae type 1 infection in Bangladesh. Clin Infect Dis 2006; 42:356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bell BP, Griffin PM, Lozano P, et al. Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections. Pediatrics 1997; 100:E12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cimolai N, Morrison BJ, Carter JE. Risk factors for the central nervous system manifestations of gastroenteritis-associated hemolytic-uremic syndrome. Pediatrics 1992; 90:616.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balestracci A, Ezquer M, Elmo ME, et al. Ibuprofen-associated acute kidney injury in dehydrated children with acute gastroenteritis. Pediatr Nephrol 2015; 30:1873.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mody RK, Gu W, Griffin PM, et al. Postdiarrheal hemolytic uremic syndrome in United States children: clinical spectrum and predictors of in-hospital death. J Pediatr 2015; 166:1022.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaplan BS, Thomson PD, de Chadarévian JP. The hemolytic uremic syndrome. Pediatr Clin North Am 1976; 23:761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005; 365:1073.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weil BR, Andreoli SP, Billmire DF. Bleeding risk for surgical dialysis procedures in children with hemolytic uremic syndrome. Pediatr Nephrol 2010; 25:1693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harkness DR, Byrnes JJ, Lian EC, et al. Hazard of platelet transfusion in thrombotic thrombocytopenic purpura. JAMA 1981; 246:1931.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lind SE. Thrombocytopenic purpura and platelet transfusion. Ann Intern Med 1987; 106:478.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balestracci A, Martin SM, Toledo I, et al. Impact of platelet transfusions in children with post-diarrheal hemolytic uremic syndrome. Pediatr Nephrol 2013; 28:919.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ardissino G, Tel F, Possenti I, et al. Early Volume Expansion and Outcomes of Hemolytic Uremic Syndrome. Pediatrics 2016; 137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coccia PA, Ramírez FB, Suárez ADC, et al. Acute peritoneal dialysis, complications and outcomes in 389 children with STEC-HUS: a multicenter experience. Pediatr Nephrol 2021; 36:1597.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Powell HR, Rotenberg E, Williams AL, McCredie DA. Plasma renin activity in acute poststreptococcal glomerulonephritis and the haemolytic-uraemic syndrome. Arch Dis Child 1974; 49:802.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Dyck M, Proesmans W. Renoprotection by ACE inhibitors after severe hemolytic uremic syndrome. Pediatr Nephrol 2004; 19:688.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caletti MG, Lejarraga H, Kelmansky D, Missoni M. Two different therapeutic regimes in patients with sequelae of hemolytic-uremic syndrome. Pediatr Nephrol 2004; 19:1148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown CC, Garcia X, Bhakta RT, et al. Severe Acute Neurologic Involvement in Children With Hemolytic-Uremic Syndrome. Pediatrics 2021; 147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brandt JR, Fouser LS, Watkins SL, et al. Escherichia coli O 157:H7-associated hemolytic-uremic syndrome after ingestion of contaminated hamburgers. J Pediatr 1994; 125:519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siegler RL. Spectrum of extrarenal involvement in postdiarrheal hemolytic-uremic syndrome. J Pediatr 1994; 125:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tanné C, Javouhey E, Boyer O, et al. Cardiac involvement in pediatric hemolytic uremic syndrome. Pediatr Nephrol 2022; 37:3215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keenswijk W, Raes A, Vande Walle J. Is eculizumab efficacious in Shigatoxin-associated hemolytic uremic syndrome? A narrative review of current evidence. Eur J Pediatr 2018; 177:311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Percheron L, Gramada R, Tellier S, et al. Eculizumab treatment in severe pediatric STEC-HUS: a multicenter retrospective study. Pediatr Nephrol 2018; 33:1385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giordano P, Netti GS, Santangelo L, et al. A pediatric neurologic assessment score may drive the eculizumab-based treatment of Escherichia coli-related hemolytic uremic syndrome with neurological involvement. Pediatr Nephrol 2019; 34:517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walsh PR, Johnson S. Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome. Pediatr Nephrol 2019; 34:1485.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monet-Didailler C, Chevallier A, Godron-Dubrasquet A, et al. Outcome of children with Shiga toxin-associated haemolytic uraemic syndrome treated with eculizumab: a matched cohort study. Nephrol Dial Transplant 2020; 35:2147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wildes DM, Harvey S, Costigan CS, et al. Eculizumab in STEC-HUS: a paradigm shift in the management of pediatric patients with neurological involvement. Pediatr Nephrol 2024; 39:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lapeyraque AL, Malina M, Fremeaux-Bacchi V, et al. Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med 2011; 364:2561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delmas Y, Vendrely B, Clouzeau B, et al. Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab. Nephrol Dial Transplant 2014; 29:565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pape L, Hartmann H, Bange FC, et al. Eculizumab in Typical Hemolytic Uremic Syndrome (HUS) With Neurological Involvement. Medicine (Baltimore) 2015; 94:e1000.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gitiaux C, Krug P, Grevent D, et al. Brain magnetic resonance imaging pattern and outcome in children with haemolytic-uraemic syndrome and neurological impairment treated with eculizumab. Dev Med Child Neurol 2013; 55:758.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Selvathesan N, Wong W, Prestidge C. Eculizumab in STEC-HUS with severe neurological involvement: a New Zealand perspective. Pediatr Nephrol 2023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loos S, Ahlenstiel T, Kranz B, et al. An outbreak of Shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children. Clin Infect Dis 2012; 55:753.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kemper MJ. Outbreak of hemolytic uremic syndrome caused by E. coli O104:H4 in Germany: a pediatric perspective. Pediatr Nephrol 2012; 27:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Menne J, Nitschke M, Stingele R, et al. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ 2012; 345:e4565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garnier A, Brochard K, Kwon T, et al. Efficacy and Safety of Eculizumab in Pediatric Patients Affected by Shiga Toxin-Related Hemolytic and Uremic Syndrome: A Randomized, Placebo-Controlled Trial. J Am Soc Nephrol 2023; 34:1561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim Y, Miller K, Michael AF. Breakdown products of C3 and factor B in hemolytic-uremic syndrome. J Lab Clin Med 1977; 89:845.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monnens L, Molenaar J, Lambert PH, et al. The complement system in hemolytic-uremic syndrome in childhood. Clin Nephrol 1980; 13:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thurman JM, Marians R, Emlen W, et al. Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009; 4:1920.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ståhl AL, Sartz L, Karpman D. Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood 2011; 117:5503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buelli S, Zoja C, Remuzzi G, Morigi M. Complement Activation Contributes to the Pathophysiology of Shiga Toxin-Associated Hemolytic Uremic Syndrome. Microorganisms 2019; 7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orth D, Khan AB, Naim A, et al. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J Immunol 2009; 182:6394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poolpol K, Orth-Höller D, Speth C, et al. Interaction of Shiga toxin 2 with complement regulators of the factor H protein family. Mol Immunol 2014; 58:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colic E, Dieperink H, Titlestad K, Tepel M. Management of an acute outbreak of diarrhoea-associated haemolytic uraemic syndrome with early plasma exchange in adults from southern Denmark: an observational study. Lancet 2011; 378:1089.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosales A, Hofer J, Zimmerhackl LB, et al. Need for long-term follow-up in enterohemorrhagic Escherichia coli-associated hemolytic uremic syndrome due to late-emerging sequelae. Clin Infect Dis 2012; 54:1413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boyce TG, Swerdlow DL, Griffin PM. Escherichia coli O157:H7 and the hemolytic-uremic syndrome. N Engl J Med 1995; 333:364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loirat C, Beaufils F, Sonsino E, et al. [Treatment of childhood hemolytic-uremic syndrome with urokinase. Cooperative controlled trial]. Arch Fr Pediatr 1984; 41:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Damme-Lombaerts R, Proesmans W, Van Damme B, et al. Heparin plus dipyridamole in childhood hemolytic-uremic syndrome: a prospective, randomized study. J Pediatr 1988; 113:913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trachtman H, Cnaan A, Christen E, et al. Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial. JAMA 2003; 290:1337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bergstein JM, Riley M, Bang NU. Role of plasminogen-activator inhibitor type 1 in the pathogenesis and outcome of the hemolytic uremic syndrome. N Engl J Med 1992; 327:755.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kruez W, Linde R, Becker S, Seifried E. Successful treatment of haemolytic uraemic syndrome with recombinant tissue-type plasminogen activator. Lancet 1993; 341:1665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siegler RL, Pavia AT, Christofferson RD, Milligan MK. A 20-year population-based study of postdiarrheal hemolytic uremic syndrome in Utah. Pediatrics 1994; 94:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siegler RL, Milligan MK, Burningham TH, et al. Long-term outcome and prognostic indicators in the hemolytic-uremic syndrome. J Pediatr 1991; 118:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fitzpatrick MM, Shah V, Trompeter RS, et al. Long term renal outcome of childhood haemolytic uraemic syndrome. BMJ 1991; 303:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loos S, Aulbert W, Hoppe B, et al. Intermediate Follow-up of Pediatric Patients With Hemolytic Uremic Syndrome During the 2011 Outbreak Caused by E. coli O104:H4. Clin Infect Dis 2017; 64:1637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alconcher LF, Coccia PA, Suarez ADC, et al. Hyponatremia: a new predictor of mortality in patients with Shiga toxin-producing Escherichia coli hemolytic uremic syndrome. Pediatr Nephrol 2018; 33:1791.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oakes RS, Siegler RL, McReynolds MA, et al. Predictors of fatality in postdiarrheal hemolytic uremic syndrome. Pediatrics 2006; 117:1656.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spinale JM, Ruebner RL, Copelovitch L, Kaplan BS. Long-term outcomes of Shiga toxin hemolytic uremic syndrome. Pediatr Nephrol 2013; 28:2097.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garg AX, Suri RS, Barrowman N, et al. Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression. JAMA 2003; 290:1360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fitzpatrick MM, Shah V, Trompeter RS, et al. Interleukin-8 and polymorphoneutrophil leucocyte activation in hemolytic uremic syndrome of childhood. Kidney Int 1992; 42:951.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oakes RS, Kirkham JK, Nelson RD, Siegler RL. Duration of oliguria and anuria as predictors of chronic renal-related sequelae in post-diarrheal hemolytic uremic syndrome. Pediatr Nephrol 2008; 23:1303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balestracci A, Meni Battaglia L, Toledo I, et al. Duration of prodromal phase and severity of hemolytic uremic syndrome. Pediatr Nephrol 2024; 39:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spizzirri FD, Rahman RC, Bibiloni N, et al. Childhood hemolytic uremic syndrome in Argentina: long-term follow-up and prognostic features. Pediatr Nephrol 1997; 11:156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alconcher LF, Lucarelli LI, Bronfen S. Long-term kidney outcomes in non-dialyzed children with Shiga-toxin Escherichia coli associated hemolytic uremic syndrome. Pediatr Nephrol 2023; 38:2131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monet-Didailler C, Godron-Dubrasquet A, Madden I, et al. Long-term outcome of diarrhea-associated hemolytic uremic syndrome is poorly related to markers of kidney injury at 1-year follow-up in a population-based cohort. Pediatr Nephrol 2019; 34:657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Repetto HA. Epidemic hemolytic-uremic syndrome in children. Kidney Int 1997; 52:1708.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Georgaki-Angelaki HN, Steed DB, Chantler C, Haycock GB. Renal function following acute renal failure in childhood: a long term follow-up study. Kidney Int 1989; 35:84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kreuzer M, Sollmann L, Ruben S, et al. Endothelial dysfunction during long-term follow-up in children with STEC hemolytic-uremic syndrome. Pediatr Nephrol 2017; 32:1005.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eijgenraam FJ, Donckerwolcke RA, Monnens LA, et al. Renal transplantation in 20 children with hemolytic-uremic syndrome. Clin Nephrol 1990; 33:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bassani CE, Ferraris J, Gianantonio CA, et al. Renal transplantation in patients with classical haemolytic-uraemic syndrome. Pediatr Nephrol 1991; 5:607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gagnadoux MF, Habib R, Niaudet P, Broyer M. Results of renal transplantation in childhood hemolytic-uremic syndrome. J Am Soc Nephrol 1996; 7:1908.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller RB, Burke BA, Schmidt WJ, et al. Recurrence of haemolytic-uraemic syndrome in renal transplants: a single-centre report. Nephrol Dial Transplant 1997; 12:1425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Müller T, Sikora P, Offner G, et al. Recurrence of renal disease after kidney transplantation in children: 24 years of experience in a single center. Clin Nephrol 1998; 49:82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loirat C, Niaudet P. The risk of recurrence of hemolytic uremic syndrome after renal transplantation in children. Pediatr Nephrol 2003; 18:1095.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calderon-Margalit R, Golan E, Twig G, et al. History of Childhood Kidney Disease and Risk of Adult End-Stage Renal Disease. N Engl J Med 2018; 378:428.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6097 Version 64.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15728781" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Hemolytic uremic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27989322" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28242109" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Haemolytic uraemic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31198225" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : An updated classification of thrombotic microangiopathies and treatment of complement gene variant-mediated thrombotic microangiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25859752" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : An international consensus approach to the management of atypical hemolytic uremic syndrome in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37819955" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Shiga Toxin-Producing Escherichia coli and the Hemolytic-Uremic Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27893870" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Associations Between Hydration Status, Intravenous Fluid Administration, and Outcomes of Patients Infected With Shiga Toxin-Producing Escherichia coli: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31125419" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Predicting Hemolytic Uremic Syndrome and Renal Replacement Therapy in Shiga Toxin-producing Escherichia coli-infected Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32681274" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Fluid restriction versus volume expansion in children with diarrhea-associated HUS: a retrospective observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34046736" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Hemoconcentration and predictors in Shiga toxin-producing E. coli-hemolytic uremic syndrome (STEC-HUS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34219224" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Interventions for preventing diarrhoea-associated haemolytic uraemic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34871193" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Why antibiotics should not be used to treat Shiga toxin-producing Escherichia coli infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26917812" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Shiga Toxin-Producing Escherichia coli Infection, Antibiotics, and Risk of Developing Hemolytic Uremic Syndrome: A Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16392080" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Low risk of hemolytic uremic syndrome after early effective antimicrobial therapy for Shigella dysenteriae type 1 infection in Bangladesh.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9200386" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1408519" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Risk factors for the central nervous system manifestations of gastroenteritis-associated hemolytic-uremic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25895445" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Ibuprofen-associated acute kidney injury in dehydrated children with acute gastroenteritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25661408" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Postdiarrheal hemolytic uremic syndrome in United States children: clinical spectrum and predictors of in-hospital death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/792781" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : The hemolytic uremic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15781103" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20422224" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Bleeding risk for surgical dialysis procedures in children with hemolytic uremic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7197306" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Hazard of platelet transfusion in thrombotic thrombocytopenic purpura.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3813251" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Thrombocytopenic purpura and platelet transfusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23386110" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Impact of platelet transfusions in children with post-diarrheal hemolytic uremic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26644486" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Early Volume Expansion and Outcomes of Hemolytic Uremic Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33394193" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Acute peritoneal dialysis, complications and outcomes in 389 children with STEC-HUS: a multicenter experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4372955" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Plasma renin activity in acute poststreptococcal glomerulonephritis and the haemolytic-uraemic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15064939" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Renoprotection by ACE inhibitors after severe hemolytic uremic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15221428" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Two different therapeutic regimes in patients with sequelae of hemolytic-uremic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33579812" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Severe Acute Neurologic Involvement in Children With Hemolytic-Uremic Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7931869" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Escherichia coli O 157:H7-associated hemolytic-uremic syndrome after ingestion of contaminated hamburgers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7931868" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Spectrum of extrarenal involvement in postdiarrheal hemolytic-uremic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35286451" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Cardiac involvement in pediatric hemolytic uremic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29288280" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Is eculizumab efficacious in Shigatoxin-associated hemolytic uremic syndrome? A narrative review of current evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29572749" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Eculizumab treatment in severe pediatric STEC-HUS: a multicenter retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30362078" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : A pediatric neurologic assessment score may drive the eculizumab-based treatment of Escherichia coli-related hemolytic uremic syndrome with neurological involvement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30058046" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31411695" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Outcome of children with Shiga toxin-associated haemolytic uraemic syndrome treated with eculizumab: a matched cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37491519" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Eculizumab in STEC-HUS: a paradigm shift in the management of pediatric patients with neurological involvement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21612462" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Eculizumab in severe Shiga-toxin-associated HUS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24293658" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26091445" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Eculizumab in Typical Hemolytic Uremic Syndrome (HUS) With Neurological Involvement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23659643" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Brain magnetic resonance imaging pattern and outcome in children with haemolytic-uraemic syndrome and neurological impairment treated with eculizumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/38032416" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Eculizumab in STEC-HUS with severe neurological involvement: a New Zealand perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22670043" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : An outbreak of Shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22160440" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Outbreak of hemolytic uremic syndrome caused by E. coli O104:H4 in Germany: a pediatric perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22815429" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37303085" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Efficacy and Safety of Eculizumab in Pediatric Patients Affected by Shiga Toxin-Related Hemolytic and Uremic Syndrome: A Randomized, Placebo-Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/845484" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Breakdown products of C3 and factor B in hemolytic-uremic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7379368" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : The complement system in hemolytic-uremic syndrome in childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19820137" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21447825" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30634669" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Complement Activation Contributes to the Pathophysiology of Shiga Toxin-Associated Hemolytic Uremic Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19414792" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24317278" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Interaction of Shiga toxin 2 with complement regulators of the factor H protein family.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21871657" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Management of an acute outbreak of diarrhoea-associated haemolytic uraemic syndrome with early plasma exchange in adults from southern Denmark: an observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22412065" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Need for long-term follow-up in enterohemorrhagic Escherichia coli-associated hemolytic uremic syndrome due to late-emerging sequelae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7609755" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Escherichia coli O157:H7 and the hemolytic-uremic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6372729" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : [Treatment of childhood hemolytic-uremic syndrome with urokinase. Cooperative controlled trial].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3183852" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Heparin plus dipyridamole in childhood hemolytic-uremic syndrome: a prospective, randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12966125" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1501651" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Role of plasminogen-activator inhibitor type 1 in the pathogenesis and outcome of the hemolytic uremic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8100032" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Successful treatment of haemolytic uraemic syndrome with recombinant tissue-type plasminogen activator.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8008534" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : A 20-year population-based study of postdiarrheal hemolytic uremic syndrome in Utah.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1993944" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Long-term outcome and prognostic indicators in the hemolytic-uremic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1912857" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Long term renal outcome of childhood haemolytic uraemic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28329394" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Intermediate Follow-up of Pediatric Patients With Hemolytic Uremic Syndrome During the 2011 Outbreak Caused by E. coli O104:H4.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29961127" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Hyponatremia: a new predictor of mortality in patients with Shiga toxin-producing Escherichia coli hemolytic uremic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16651320" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Predictors of fatality in postdiarrheal hemolytic uremic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23288350" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Long-term outcomes of Shiga toxin hemolytic uremic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12966129" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1453586" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Interleukin-8 and polymorphoneutrophil leucocyte activation in hemolytic uremic syndrome of childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18465151" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Duration of oliguria and anuria as predictors of chronic renal-related sequelae in post-diarrheal hemolytic uremic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37526769" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Duration of prodromal phase and severity of hemolytic uremic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9090653" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Childhood hemolytic uremic syndrome in Argentina: long-term follow-up and prognostic features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36595068" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Long-term kidney outcomes in non-dialyzed children with Shiga-toxin Escherichia coli associated hemolytic uremic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30368614" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Long-term outcome of diarrhea-associated hemolytic uremic syndrome is poorly related to markers of kidney injury at 1-year follow-up in a population-based cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9407523" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Epidemic hemolytic-uremic syndrome in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2709664" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Renal function following acute renal failure in childhood: a long term follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28180952" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Endothelial dysfunction during long-term follow-up in children with STEC hemolytic-uremic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2311309" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Renal transplantation in 20 children with hemolytic-uremic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1911148" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Renal transplantation in patients with classical haemolytic-uraemic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Results of renal transplantation in childhood hemolytic-uremic syndrome
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9249780" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Recurrence of haemolytic-uraemic syndrome in renal transplants: a single-centre report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9524777" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Recurrence of renal disease after kidney transplantation in children: 24 years of experience in a single center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13680331" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : The risk of recurrence of hemolytic uremic syndrome after renal transplantation in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29385364" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : History of Childhood Kidney Disease and Risk of Adult End-Stage Renal Disease.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
